Skip to content
Peptigraph home

CJC-1295 and Sermorelin Together: What Is Known

CJC-1295 and Sermorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.[4]Growth hormoneGHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[16]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 13 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 5 of 12 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Half-life, Evidence strength are the same or both unknown.

FieldCJC-1295Sermorelin
Also calledCJC, mod GRF, GRF 1-29—
FDA statusNot FDA approved · research chemicalCompounded by prescription
Human studies we summarised4 human (1 randomized or controlled) of 7 summarised6 human (1 randomized or controlled) of 9 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg2 mg, 5 mg, 9 mg, 15 mg
Related tools

CJC-1295 vs Sermorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

Two GHRH analogues with different persistence

CJC-1295 binds albumin after injection, and one study of it reports a half-life of 8 days.[5]

In that study GH pulses kept their normal frequency and size, while trough GH levels rose 7.5-fold.[5]

For comparison, sermorelin's active fragment GHRH-(1-29), given once daily to prepubertal children with GH deficiency in an open-label trial, took height velocity from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months.[16]

No head-to-head or combined trial

A PubMed search on 2 Oct 2026 for CJC-1295 with sermorelin matched 13 records. The ten shown in the cached results are anti-doping detection methods and sports-medicine reviews.

Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (sermorelin[tiab] OR Geref[tiab]); records matched 13; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

One anti-doping study that lists both peptides is a urine metabolism and detection study, not a study of giving them together.[3]

One review notes that most published studies examine therapeutic use under controlled dosing, not the combined protocols common in bodybuilding, and flags cardiovascular strain and insulin resistance as emerging risks.[19]

Regulatory and sport status

A Drugs@FDA search for CJC-1295 returns nothing approved.[20]

FDA's safety note for CJC-1295 also says available clinical data are limited.[21]

WADA's prohibited list names both CJC-1295 and sermorelin as GHRH analogues.[1]

Common questions

CJC-1295 vs sermorelin: which lasts longer?

Only CJC-1295 has a half-life cited here: 8 days in its albumin-binding form, in one study. No sermorelin half-life is cited.[5]

Can you use CJC-1295 and sermorelin together?

The cached PubMed search found no trial of the pair. A review notes that studies mostly test single agents under controlled dosing, not the combined protocols used in bodybuilding.[19]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  5. 5Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  6. 6Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  7. 7PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  10. 10Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  11. 11Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  12. 12PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  17. 17PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  18. 18PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  19. 19A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.The Journal of sports medicine and physical fitness · 2026PMID 41880199Accessed 2 Oct 2026
  20. 20Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  21. 21Official web pageOfficial web page · web page

Found an error? Report a correction.